Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
Madison, N.J., October 10, 2008 – Wyeth (NYSE:WYE) announced today that the jury in the case of Danny Crowder (Individually and as Administrator of the Estate of Edna Faye Crowder) v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth.
“We believe this unanimous verdict was supported by the evidence,” says Bob Nicholas, an attorney from Reed Smith, who represented Wyeth. “While Mrs. Crowder’s death was tragic, the medical evidence clearly demonstrated that her condition was unrelated to the diet drugs she used over ten years ago.”
The trial began on September 29, 2008 before The Honorable Gary S. Glazer. The plaintiff alleged the wrongful death of Mrs. Crowder caused by Primary Pulmonary Hypertension (PPH) as a result of her use of the diet drug Pondiminâ, a drug once marketed by Wyeth. The Court had earlier ruled that plaintiff could not pursue punitive damages in this case.
The plaintiff was represented by the Clark Burnett law firm of Houston, Texas.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.